

UBS Future of Humans EUR-hedged P-acc


Fund Fact Sheet

UBS Equity Funds > Multi Manager Access II > Future of Humans

Fund description

- An actively managed multi-manager global equity fund that invests in companies exposed to the global trends toward an aging population, the growth in population and increasing urbanization.
- These aspects can comprise any sectors, countries and company capitalisations in order to benefit from disruptive developments in society, resources and technology, with a focus on longevity, education, healthcare and consumer preferences.
- The exchange rate risk between USD and EUR is largely hedged.

Performance (basis EUR, net of fees)¹



— Fund performance net of fees (left-hand scale)

..... Index performance (left-hand scale)

Past performance is not a reliable indicator of future results.

Name of fund	Multi Manager Access II - Future of Humans
Share class	Multi Manager Access II - Future of Humans EUR-hedged P-acc
ISIN	LU2215385365
Securities no.	56 442 997
Bloomberg	MFOHEHP LX
Currency of fund / share class	USD/EUR
Launch date	19.10.2020
Issue/redemption	daily
Swing pricing	yes
Accounting year end	31 July
Benchmark	MSCI ACWI Net Total Return index (hedged EUR)
Distribution	Reinvestment
Management fee p.a.	1.57%
Ongoing charges p.a. ¹	1.79%
Name of the Management Company	UBS Fund Management (Luxembourg) S.A., Luxembourg
Fund domicile	Luxembourg

¹ as at 13.09.2021

in %	2017	2018	2019	2020	2021 YTD ²	LTD ³	1 year	Ø p.a. 2 years
Fund (EUR)	n.a.	n.a.	n.a.	n.a.	3.76	12.05	n.a.	n.a.
Ref. Index ⁴	n.a.	n.a.	n.a.	n.a.	12.26	23.45	n.a.	n.a.

The performance shown does not take account of any commissions, entry or exit charges.

¹ These figures refer to the past. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Source for all data and charts (if not indicated otherwise): UBS Asset Management.

² YTD: year-to-date (since beginning of the year)

³ LTD: launch-to-date

⁴ Reference Index in currency of share class (without costs)

Fund statistics

Net asset value (EUR, 30.09.2021)	112.05
Last 12 months (EUR) – high	119.63
– low	93.85
Total fund assets (EUR m)	895.15
Share class assets (EUR m)	23.23

	3 years	5 years
Beta	n.a.	n.a.
Volatility ¹		
– Fund	n.a.	n.a.
– Benchmark	n.a.	n.a.
Sharpe ratio	n.a.	n.a.
Risk free rate	n.a.	n.a.

¹ Annualised standard deviation

For more information

Internet: www.ubs.com/luxembourgfunds
Contact your client advisor

UBS Future of Humans EUR-hedged P-acc

Sector exposure (%)

	Fund	Index
Health Care	42.36	11.69
Consumer Discretionary	25.17	12.44
Communication Services	8.30	9.27
Information Technology	8.24	22.33
Financials	6.77	14.38
Real estate	3.24	2.62
Industrials	2.07	9.67
Consumer Staples	1.79	6.77
Materials	1.36	4.66
Others	0.70	6.17

10 largest equity positions (%)

	Fund	Index
Abbott Laboratories	2.55	0.32
Medtronic PLC	2.05	0.26
Amazon.com Inc	1.74	2.27
Roche Holding AG	1.71	0.39
Novo Nordisk A/S	1.69	0.25
Paycom Software Inc	1.56	0.04
Booking Holdings Inc	1.52	0.15
Moderna Inc	1.50	0.20
AstraZeneca PLC	1.50	0.28
UnitedHealth Group Inc	1.49	0.56

Market exposure (%)

	Fund	Deviation from index		Fund	Deviation from index	
United States	59.23	-0.3		Germany	2.72	+0.4
United Kingdom	5.87	+2.2		Denmark	2.45	+1.8
Switzerland	5.65	+3.2		Hong Kong	2.37	+1.6
China	5.33	+1.3		France	1.29	-1.6
Japan	4.23	-2.0		Others	8.04	-9.2
Ireland	2.82	+2.6				

Benefits

Benefit from developments driven by the meta themes education, healthcare and changing consumer preferences. Harnesses the dedicated capabilities of leading thematic portfolio managers, most of whom are not accessible via public funds.

A focus on attractively valued companies with strong links to the respective themes.

The structure allows for the addition/removal of managers as well as portfolio optimization.

Risks

A new fund with no track record, notwithstanding the investment history of the portfolio managers.

An equity fund with exposure to small, growing and innovative companies which can result in significant fluctuations in value, particularly in the short term.

The thematic focus may lead to concentrations in a specific sector or style.

The performance of actively managed funds may deviate significantly from the referenced index.

The fund can use derivatives, which may result in additional counterparty and liquidity risks.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 of Regulation (EU) 2019/2088. Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at ubs.com/am-glossary.

© UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.